摘要
肠易激综合征(irritable bowel syndrome,IBS)是一种功能性肠病,目前已有研究表明IBS的致病机制、症状的产生和持续时间可能与肠道菌群失调有关,且不同IBS亚型患者体内的肠道菌群种类有差异。IBS的发病机制尚不完全清楚,临床表现存在较大的个体差异。IBS的诊断和治疗尚未形成统一的标准。但已经有较多研究提示IBS可能与胃肠道动力、内脏高敏感性、肠道免疫反应和模式识别受体等密切相关,并且可以通过益生菌、益生元、抗生素、粪菌移植和饮食习惯等调节肠道菌群的失调,从而改善IBS的症状。这也为未来治疗IBS提供了新的思路。本文就肠道菌群的概况、IBS患者肠道菌群的特点、肠道菌群失衡导致IBS发病的可能机制以及IBS肠道菌群的相关治疗方法的研究进展作一综述。
Irritable bowel syndrome(IBS) is a kind of functional bowel diseases. The pathogenesis, symptoms and persistence of IBS may be related to intestinal flora imbalance, and the types of intestinal flora in different IBS subtypes are different. At present, the pathogenesis of IBS is still unclear, and the clinical manifestations are quite individually different. There have not yet been unified standards for the diagnosis and treatment of IBS. However, many studies suggested that IBS may be closely related to gastrointestinal motility, visceral hypersensitivity, intestinal immune response and pattern recognition receptors, and can be improved through regulation of intestinal flora imbalance by probiotics, prebiotics, antibiotics, fecal bacteria transplantation and dietary habits, which provides a new idea for the future treatment of IBS. This article reviewed the progress in researches on the overview and characteristics intestinal flora in IBS patients, the possible mechanisms of intestinal flora imbalance leading to IBS, and the treatment of IBS intestinal flora.
作者
何佳璨
周桂荣
李欣欣
宋兆辉
缪兴龙
刘丽芳
何毅
HE Jiacan;ZHOU Guirong;LI Xinxin;SONG Zhaohui;MIAO Xinglong;LIU Lifang;HE Yi(State Key Laboratory of Active Components and Efficacy of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China;不详)
出处
《中国微生态学杂志》
CAS
CSCD
2020年第1期117-124,共8页
Chinese Journal of Microecology
关键词
肠易激综合征
肠道菌群
病理生理机制
治疗
益生菌
益生元
Irritable bowel syndrome
Intestinal flora
Pathophysiological mechanism
Treatment
Probiotics
Prebiotics
作者简介
何佳璨(1995-),女,在读硕士,从事现代中药分析、中药药理学研究,E-mail:cpuhejc@126.com;通信作者:刘丽芳,博士,教授,从事生药活性成分与质量评价研究,E-mail:liulifang69@126.com;共同通信作者:何毅,博士,从事中药新药开发与研究工作,E-mail:heyi@tasly.com。
